Curis Lifesciences shareholders and shareholding pattern
NSE: CURISPharmaceuticals & Biotechnology
Last close ₹176.45down ₹8.55 (4.62%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹185.00.
Range of traded prices from listing on 14 Nov 2025 to 23 Oct 2026
₹83.60Low, 23 Mar 2026₹234.75High, 28 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹143 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Jul 2026
- 20.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 Jul 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Nov 2025
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 7 Jul 2026
- 14.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 Jul 2026
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 4,000100.0% delivered
Who owns Curis Lifesciences, filing by filing
Per cent of the company's shares. Every filing on record, from Mar 2026; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters68.03%
- Foreign institutions1.05%
- Indian institutions4.63%
- Individuals and others26.29%
Shareholding pattern, per cent
- Promoters
- Foreign institutions
- Indian institutions
- Individuals and others
| Per cent | Mar 2026Filed 21 Apr | Sep 2026Filed 21 Oct |
|---|---|---|
| 68.03% | 68.03% | |
| Indian promoters | 68.03% | 68.03% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 31.97% | 31.97% |
| Shares in issue | 80,84,434 | 80,84,434 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 58,68,368 | 58,68,368 |
| Promoters' shares locked in | 55,00,000 | 55,00,000 |
A dash is a line the filing did not state.
Curis Lifesciences promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Pawasia Siddhant J, 19.05%.
| Holder | |||
|---|---|---|---|
| Pawasia Siddhant JIndividuals and Hindu undivided families | 19.05% | 15,40,000 | 100.00% |
| Piyush Gordhanbhai AntalaIndividuals and Hindu undivided families | 15.65% | 12,65,000 | 100.00% |
| Dharmesh D PatelIndividuals and Hindu undivided families | 13.27% | 10,72,500 | 100.00% |
| Patel Jaimik MansukhlalIndividuals and Hindu undivided families | 10.89% | 8,80,000 | 100.00% |
| Pavasiya Jayntibhai DayaljibhaiIndividuals and Hindu undivided families | 6.80% | 5,50,000 | 100.00% |
| Mansukhbhai PatelIndividuals and Hindu undivided families | 2.04% | 1,65,000 | 100.00% |
| Tushar SaliaIndividuals and Hindu undivided families | 0.34% | 27,500 | 100.00% |
No promoter shares are reported as pledged. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Largest public holders of Curis Lifesciences, filing by filing
Per cent, on the same shares as the split above.
| Holder | Mar 2026Filed 21 Apr | Sep 2026Filed 21 Oct |
|---|---|---|
| S S Corporate Securities LimitedCompanies | 2.81% | 2.93% |
| Sachin KapoorResident individuals, over ₹2 lakh at face value | 2.04% | 2.33% |
| Strategic Sixth Sense Capital FundAlternative investment funds | 2.17% | 2.17% |
| Radhu Developers Private LimitedCompanies | 1.29% | 1.73% |
| Sixth Sense Securities Private LimitedOther non-institutions | 1.72% | 1.72% |
| Maiq Growth Scheme-Long OnlyAlternative investment funds | 1.51% | 1.51% |
| Zeta Global Funds (Oeic) Pcc Limited- Zeta Series A Fund PcForeign portfolio investors, category I | 1.05% | 1.05% |
| Rs Wealth Management Private LimitedOther non-institutions | 1.37% | 1.00% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. A dash is a filing that did not name the holder, which includes holding under one per cent.